@article {1912, title = {In Silico Study of the Potential of Endemic Sumatra Wild Turmeric Rhizomes (Curcuma Sumatrana: Zingiberaceae) As Anti-Cancer}, journal = {Pharmacognosy Journal}, volume = {14}, year = {2022}, month = {December 2022}, pages = {806-812}, type = {Research Article }, chapter = {806}, abstract = {

Cancer is one of the diseases that is the highest cause of death in humans. Most human cancer cells are formed as a result of over-expression of anti-apoptotic proteins. Thus, the activation of these proteins can inhibit pro-apoptotic proteins, then apoptosis will be inhibited so that other apoptotic pathways need to be activated to prevent cancer cells from developing. Current cancer treatments, such as chemotherapy using synthetic compounds, have various side effects, so research on natural based therapies can be used as an alternative in cancer treatment. Curcuma sumatrana is one of the plants of the Zingiberaceae family which is an endemic plant from Sumatra which is found along the Bukit Barisan. The research was carried out in silico by analyzing the potential bioactivity of the compounds, testing the bioavailability, toxicity, and molecular docking of the bioactive compounds from the ethanol extract of the rhizome of C. sumatrana which had been previously identified through gas chromatography-mass spectroscopy (GCMS) analysis. The results obtained that the compound 9-Acetyl-S-octahydrophenanthrene and 3-Oxoandrosta- 1,4-dien-17.beta.-spiro-2{\textquoteright}-3{\textquoteright}-oxo-oxetanecontained in C. sumatrana has the potential to be developed as an anticancer where the compound has good bioavailability value and is not toxic and potentially can trigger apoptosis. However, the results of this study need to be analyzed further with an in vitro or in vivo approach.

}, keywords = {Anticancer, C. sumatrana, in silico}, doi = {10.5530/pj.2022.14.171}, author = {Aldi Tamara Rahman and Rafia and Aiken Jethro and Putra Santoso and Viol Dhea Kharisma and Ahmad Affan Ali Murtadlo and Devi Purnamasari and Nunuk Hariani Soekamto and ANM Ansori and Kuswati and Riso Sari Mandeli and Kawther Ameen Muhammed Saeed Aledresi and Nur Farhana Mohd Yusof and Vikash Jakhmola and Maksim Rebezov and Maksim Rebezov and Rahadian Zainul and Kiran Dobhal and Tarun Parashar and Muhammad Arya Ghifari and Deffi Ayu Puspito Sari} } @article {1914, title = {An In Silico Study to Explore the Role of EGFR in Ovarian Cancer}, journal = {Pharmacognosy Journal}, volume = {14}, year = {2022}, month = {December 2022}, pages = {817-821}, type = {Research Article }, chapter = {817}, abstract = {

EGFR is a tyrosine kinase receptor that has a role in the tumorigenesis of many types of solid tumors. Aberrantly phosphorylated or overexpressed EGFR is associated with cellular proliferation, prevention of apoptosis, activation of invasion and metastasis, and stimulation of tumor-induced neovascularization. EGFR{\textquoteright}s hyperactivity has been observed in ovarian cancer. Although conventional chemotherapy and surgery for advanced ovarian cancer have improved over the years, still there is a critical need for the development of molecular targeted therapies. The major challenge for this approach is the complete understanding of the protein structure of this mega receptor. In this study, we explored this receptor using in silico tools. The protein structure of the EGFR kinase domain (PDB ID: 1M17) and co-crystal containing EGFR and PTP1B kinase domain fragment (PDB ID: 3I7Z) were obtained from the RCSB Protein Data Bank. We performed protein-protein docking using BioLuminate. It was found in this study that the DADEYL segment of EGFR (position 988-993) which includes autophosphorylated tyrosine at position 992, is the segment that is responsible for the overexpression of this receptor in ovarian cancer. There are currently two main classes of clinically-approved drugs which downregulate EGFR activity; tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (Mabs). However, treatment with both type of therapies has been met with shortcomings. Therefore, there is a need for further studies to explore the suitable ligands that can downregulate its activity.

}, keywords = {EGFR, In silico study, Protein-protein docking, Tyrosine kinases}, doi = {10.5530/pj.2022.14.173}, author = {Vikash Jakhmola and Tarun Parashar and Pallavi Ghildiyal and ANM Ansori and Rajeev Kumar Sharma and N. G. Raghavendra Rao and Kapil Kalra and Nishan Singh and Nidhi Nainwal and Rajeev Kumar Singh and M. P Singh and Vishwadeepak Kimothi and Alok Bhatt and Ashish Dimri and Ravi Kumar and Amit Semwal and Nur Sofiatul Aini and Maksim Rebezov} }